The silatecans, a novel class of lipophilic camptothecins

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 6, 2003, Pages 751-760

  Versace, Richard W ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Camptothecin (CPT); Chemotherapy; Cytotoxic agents; Silatecan; Topoisomerase I (topo I)

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYTOTOXIC AGENT; DNA TOPOISOMERASE; GIMATECAN; IRINOTECAN; KARENITECIN; LACTONE DERIVATIVE; SILANE DERIVATIVE; SILATECAN DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG UPTAKE; GLIOMA; HEMORRHAGIC CYSTITIS; HUMAN; LEUKEMIA; LIPOPHILICITY; LUNG SMALL CELL CANCER; NEUTROPENIA; NONHUMAN; OVARY CANCER; PATENT; REVIEW; SARCOMA; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

EID: 0038647786     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.6.751     Document Type: Review

References (45)

1. WALL M, WANI M, COOK CE, PALMER KH, MCPHAIL HT, SIM GA: Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. (1966) 88:3888-3890.
2. WALL M: Camptothecin and taxol: discovery to clinic. Med. Res. Rev. (1998) 18:299-314.
3. HSIANG YH, HERTZBERG R, HECHT S, LIU L: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. (1985) 260:14873-14878.
4. POMMIER Y, POURQUIER P, FAN Y, STRUMBERG D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta (1998) 1400:83-105.
5. GARCIA-CARBONERO R, SUPKO JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. (2002) 8:641-661.
6. STAKER BL, HJERRILD K, FEESE MD, BEHNKE CA, BURGIN AB, STEWART L: The mechanism of topoisomemse I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA (2002) 99:15387-15392.
7. HSIANG YH, LIHOU MG, LIU LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. (1989) 49:5077-5082.
8. SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC, KAUFMANN SH: The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. (1993) 85:271-291.
9. POTMESIL M: Camptothecins: from bench research to hospital wards. Cancer Res. (1994) 54:1431-1439.
10. JAXEL C, KOHN KW, WANI MC, WALL ME, POMMIER Y: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. (1989) 49:1465-1469.
11. FASSBERG J, STELLA VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogs. J. Pharm. Sci. (1992) 81:676-684.
12. BURKE TG, MISHRA AK, WANI MC, WALL ME: Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry (1993) 32:5352-5364.
13. BURKE TG, MI Z: Ethyl substitution at the 7-position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J. Med. Chem. (1993) 36:2580-2582.
14. BURKE TG, MI Z: The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem. (1994) 37:40-46.
15. MI Z, BURKE TG: Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry (1994) 33:10325-10336.
16. MI Z, MALAK H, BURKE TG: Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry (1995) 34:13722-13728.
17. MOERTEL CG, SCHUTT AJ, REITEMEIER RJ, HAHN RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemo. Rep. Part 1 (1972) 56:95-101.
18. SCOTT DO, BINDRA D, SUTTON SC, STELLA VJ: Urinary and biliary disposition of the lactone and carboxylate forms of 20(2)-camptothecin in rats. Drug Metab. Disp. (1994) 22:438-442.
19. GERRITS CJ, de JONGE MJ, SCHELLENS JH, STOTER G, VERWEIJ J: Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer (1997) 76:952-962.
20. MI Z, BURKE TG: Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry (1994) 33:12540-12545.
21. SALTZ LB: Clinical use of irinotecan: current status and future considerations. Oncologist (1997) 2:402-409.
22. HOCHSTER H, LIEBES L, SPEYER J et al.: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Onc. (1994) 12:553-559.
23. GERRITS CJH: SCHELLENS JHM, BURRIS H et al.: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin). Clin. Cancer Res. (1999) 5:69-75.
24. HERBEN VM, ROSING H, TEN BOKKEL HUININK WW et al.: Oral topotecan: bioavailability and effect of food co-administration. Br. J. Cancer (1999) 80:1380-1386.
25. O'CONNOR PM, KERRIGAN D, BERTRAND R, KOHN KW, POMMIER Y: 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells. Cancer Comm. (1990) 2:395-400.
26. DALLAVALLE S, FERRARI A, BIASOTTI B, MERLINI L, PENCO S, GALLO G et al.: Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J. Med. Chem. (2001) 44:3264-3274.
27. JOSIEN H, BOM D, CURRAN DP, ZHENG YH, CHOU TC: 7-Silylcamptothecins (silatecans): a new family of camptothecin antitumor agents. Bioorg. Med. Chem. Lett. (1997) 7:3189-3194.
28. LAVERGNE O, LESUEUR-GINOT L, RODAS FP, BIGG DCH: BN 80245: an E-ring-modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg. Med. Chem. Lett. (1997) 7:2235-2238.
29. LAVERGNE O, LESUEUR-GINOT L, RODAS FP et al.: Homo camptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogs. J. Med. Chem. (1998) 41:5410-5419.
30. BAILLY C: Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit. Rev. Onc. Hem. (2003) 45:91-108.
31. DALLAVALLE S, MERFINI L, PENCO S, ZUNINO F: Perspectives in camptothecin development. Expert Opin. Ther. Patents (2002) 12:837-844.
32. SESSA C, HESS D, BASELGA J et al.: Concerted escalation of dose and dosing-duration in a Phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. ASCO Annual Meeting (2002):Abst.386.
33. KEIR ST, HAUSHEER F, LAWLESS AA, BIGNER DD, FRIEDMAN HS: Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20(S)-camptothecin [karenitecin] against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemo. Pharm. (2001) 48:83-87.
34. SCHILSKY R, HAUSHEER F, BERTUCCI D, BERGHORN E, KINDLER H, RATAIN M: Phase I trial of karenitecin (KT) administered intravenously daily for five consecutive days in patients with advanced solid tumors using accelerated dose titration. ASCO Annual Meeting (2000):Abst.758.
35. BOM D, CURRAN DP, CHAVAN AJ et al.: Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J. Med. Chem. (1999) 42:3018-3022.
36. DU W, GABARDA AE, BOM D, CURRAN DP: The combinatorial synthesis of racemic homosilatecan libraries via a cascade radical annulation. In: The Camptothecins. Unfolding their Anti-cancer potential. Liehr JG, Giovanella BC, Verschraegen CF (Eds), New York Academy of Sciences, USA (2000) 922:317-319.
37. DU W, KASKAR B, BLUMBERGS P, SUBRAMANIAN PK, CURRAN D: Semisynthesis of DB-67 and other silatecans from camptothecin by thiol-promoted addition of silyl radicals. Bioorg. Med. Chem. (2003) 11:451-458.
38. BOM D, CURRAN DP, KRUSZEWSKI S, ZIMMER SG, STRODE JT, KOHLHAGEN G: The novel silatecan 7-tertbutyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. (2000) 43:3970-3980.
39. POLLACK IF, ERFF M, BOM D, BURKE TG, STRODE JT, CURRAN DP: Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res. (1999) 59:4898-4905.
40. BURKE TG (P.I.): The development of a liposomal formulation of highly lipophilic 7-t-butyldimethylsilyl-10-hydroxycamptothecin (db67). National Cancer Institute RAID Project.
41. VAN HATTUM AH, PINEDO HM, SCHLUPER HMM, HAUSHEER FH, BOVEN E: New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int. J. Cancer (2000) 88:260-266.
42. VAN HATTUM AH, SCHLUPER HMM, HAUSHEER FH, PINEDO HM BOVEN E: Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int. J. Cancer (2002) 100:22-29.
43. MALIEPAARD M, VAN GASTELEN MA. TOHGO A et al.: Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using nonsubstrate drugs or the BCRP inhibitor GF 120918. Clin. Cancer Res. (2001) 7:935-941.
44. ALLEN JD, SCHINKEL AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Therap. (2002) 1:427-434.
45. THOMPSON P, BERG S, GURURANGAN S et al.: A Phase I study of karenitecin in children. AACR Annual Meeting (2002):Abstr.2748.